ACTIVE PHARMACEUTICAL INGREDIENTS

Comprehensive Study Notes

Dr. Priyajit Banerjee | Swami Vivekananda University

 Section I: Fundamentals of APIs

1.1 What Are Active Pharmaceutical Ingredients (APIs)?

An Active Pharmaceutical Ingredient (API) is any substance or mixture of substances intended to be used in the
manufacture of a pharmaceutical dosage form, and which, when so used, becomes an active ingredient of that
product. APIs are the biologically active components responsible for the intended therapeutic effect in patients.
Unlike excipients, APIs directly interact with biological targets — receptors, enzymes, nucleic acids, or pathogens
— to produce a pharmacological response. They form the scientific and commercial foundation of every drug
product globally.

📌 Key Definition
ICH Q7 defines an API as: 'Any substance or mixture of substances intended to be used in the
manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes
an active ingredient of the drug product.' APIs may be derived from chemical synthesis, fermentation,
plant extraction, or recombinant biotechnology.

1.2 APIs vs. Excipients

A fundamental distinction in pharmaceutical science is between active ingredients (APIs) and inactive ingredients
(excipients). Understanding this difference is essential for formulation design, regulatory submission, and quality
control.

Parameter API Excipient

Definition Biologically active substance Inactive ingredient aiding delivery,

causing the therapeutic effect stability, or palatability

Pharmacological Role Direct interaction with body targets No direct therapeutic action

Examples Amoxicillin, Insulin, Adalimumab Lactose, Magnesium stearate, PEG

Regulatory Focus Strict purity, potency, identity Generally recognized as safe (GRAS)
testing standards

Concentration in product Low (mg to g range) Often major component by weight

Manufacturing controls GMP, ICH Q7, full batch records GMP with less stringent controls

Source Synthetic, biological, or natural Chemical or natural; widely sourced

Excipients serve critical functions: binders hold tablets together, disintegrants facilitate breakdown in the GI tract,
fillers provide bulk, lubricants reduce friction during tablet compression, coatings protect from moisture or mask
taste, and preservatives extend shelf life. While excipients are pharmacologically inert, they profoundly affect
bioavailability, stability, and patient compliance.
 📌 NB
A key ICH guideline governing excipient is ICH Q8 (Pharmaceutical Development), while APIs are
governed by ICH Q7 (GMP for APIs). Both documents are foundational to regulatory submissions
(CTD format, Module 3).

1.3 Classification of APIs: Small Molecules, Peptides & Biologics

APIs are classified into three primary categories based on their molecular origin, size, structural complexity, and
method of manufacture. This classification has profound implications for chemistry, manufacturing, controls
(CMC), regulatory pathway, and clinical development strategy.

Criterion Small Molecules Peptides Biologics

Molecular Weight < 900 Daltons < 10 kDa (2–50 amino > 5,000 Daltons
acids)

Structure Simple organic Short amino acid chains Large, complex

compounds proteins/nucleic acids

Synthesis Chemical synthesis Chemical (SPPS) or Recombinant DNA / cell

biological culture

Stability Highly stable Moderate; oral Sensitive to pH, temp,

administration limited oxidation

Manufacturing Cost Low to moderate Moderate to high High

Market Share ~60–70% ~5–10% ~20–30% (fastest

growing)

Route of admin. Oral, topical, injectable Mostly injectable / Mostly injectable / IV

intranasal infusion

Examples Aspirin, Metformin, Insulin, GLP-1 agonists, Adalimumab,

Atorvastatin Oxytocin Trastuzumab, mRNA
vaccines

Generic pathway ANDA (generic) Modified ANDA or Biosimilar (351(k) / EMA

505(b)(2) guidelines)

Small Molecule APIs

Small molecule APIs are organic compounds with molecular weights typically below 900 Daltons. They are the
most traditional class of pharmaceuticals, produced through well-established multi-step chemical synthesis
pathways. These molecules are characterized by excellent shelf stability, predictable pharmacokinetics, cost-
effective production, and oral bioavailability in most cases.
Therapeutic applications span all disease categories: cardiovascular (losartan, atorvastatin, metoprolol), infectious
diseases (amoxicillin, ciprofloxacin), oncology (imatinib, tamoxifen, 5-fluorouracil), CNS disorders (sertraline,
levodopa, donepezil), pain management (ibuprofen, paracetamol), and diabetes (metformin, glibenclamide,
pioglitazone).
• Advantages: Cost-effective, stable, oral bioavailability, established regulatory pathway
• Limitations: Off-target effects, hepatic metabolism causing DDIs, cannot replicate complex biologic
functions

Peptide APIs
Peptide APIs are short chains of amino acids (typically 2–50 residues) linked by peptide bonds, with molecular
weights generally below 10 kDa. They occupy a unique niche between small molecules and biologics, offering high
receptor selectivity combined with relatively simpler manufacturing compared to full proteins.
Peptides are manufactured by Solid-Phase Peptide Synthesis (SPPS), solution-phase synthesis, or recombinant
biological methods. Their intermediate stability requires specialized formulation — often lyophilization and cold-
chain storage. Most are administered parenterally due to proteolytic degradation in the GI tract.
• Key examples: Insulin (diabetes), GLP-1 receptor agonists (semaglutide for T2DM & obesity), oxytocin
(obstetrics), ACTH (endocrinology), antimicrobial peptides

Biologic APIs
Biologic APIs are large, complex molecules derived from living organisms through biotechnological methods.
These include therapeutic proteins, monoclonal antibodies, vaccines, nucleic acid therapies, cell therapies, and
gene therapies — typically exceeding 5,000 Daltons in molecular weight.
Defining characteristics include tertiary and quaternary protein structures with multiple functional domains,
production via recombinant DNA technology in living cells (mammalian, bacterial, or yeast), natural
microheterogeneity in post-translational modifications, and multimodal mechanisms engaging both receptors and
the immune system.

Biologic Category Molecular Type Source / Production Typical Application

Therapeutic Proteins Recombinant Mammalian/bacterial cells Enzyme replacement, hormone

proteins therapy

Monoclonal Immunoglobulins Hybridoma/CHO cells Cancer, autoimmune disease

Antibodies

Antibody-Drug Antibody-drug fusion Engineered cell lines Targeted cancer therapy

Conjugates

Vaccines Immunogens Viral particles, recombinant Infectious disease prevention

proteins

Gene Therapies DNA/RNA sequences Viral vectors, nucleotides Genetic disease correction

Biosimilars Copies of reference Cell culture replication Cost-effective biologic

biologics alternative
1.4 Global API Industry Overview
The global API market is a multi-hundred-billion-dollar industry that underpins the entire pharmaceutical supply
chain. APIs are manufactured primarily in Asia — particularly India and China — and distributed to finished dose
form manufacturers worldwide.
• India contributes approximately 20–25% of global API supply, serving as the 'pharmacy of the world' for
generic APIs
• China dominates in key starting material (KSM) and intermediates production
• The US, Europe, and Japan maintain significant domestic capacity for innovative/patented APIs
• Market segments: Small molecules (~60–70%), Biologics (~20–30%, fastest growing), Peptides (~5–10%)

Key industry drivers include patent expiries (generic boom), biosimilar approvals, pandemic-driven supply chain
diversification, regulatory harmonization (ICH), and government initiatives for domestic API production (India's
PLI scheme, US BARDA programs).

India's API dominance is built on cost-competitive chemistry, a large pool of trained chemists,
established regulatory compliance, and proximity to raw material suppliers. However,
overdependence on Chinese KSMs remains a strategic vulnerability highlighted during COVID-19.
 Section II: Chemistry & Biology of APIs

2.1 Small Molecule Synthesis

Small molecule APIs are manufactured through organic synthesis — a sequence of chemical reactions that build
molecular complexity from simpler starting materials. The design of a synthetic route (route scouting) considers
yield, stereoselectivity, cost of reagents, safety, environmental footprint (green chemistry), scalability, and
regulatory acceptability of reagents and solvents.

Key Concepts in Synthesis

• Retrosynthetic analysis: Working backward from target molecule to identify feasible precursors
• Convergent synthesis: Building multiple subunits in parallel, then joining — preferred for complex
molecules
• Linear synthesis: Each step builds on the previous; simpler but accumulates yield losses
• Stereochemistry control: Chiral centers in APIs often require asymmetric synthesis or chiral resolution
• Protecting groups: Temporarily block reactive functional groups to enable selective reactions

📌 ICH Q3A & Q3B

These guidelines govern impurity profiling in new drug substances. Synthesis introduces potential
genotoxic impurities (GTIs), residual solvents (ICH Q3C), and elemental impurities (ICH Q3D) — all of
which must be controlled to acceptable limits in the final API.

2.2 Peptide APIs & Solid-Phase Peptide Synthesis (SPPS)

Therapeutic peptides are synthesized primarily by Solid-Phase Peptide Synthesis (SPPS), a technique developed
by R.B. Merrifield (Nobel Prize, 1984). In SPPS, the peptide chain is assembled stepwise on an insoluble resin
support, allowing easy washing away of excess reagents after each coupling step.

SPPS Process Flow

1. Resin Loading: C-terminal amino acid anchored to solid resin via its carboxyl group
2. Deprotection: Fmoc (or Boc) protecting group removed from N-terminus
3. Coupling: Activated next amino acid (The carboxylic acid of the incoming amino acid is activated by
converting it into a highly reactive species, like an active ester or anhydride) joined to growing chain via
peptide bond.
4. Washing: Excess reagents removed; cycle repeated for each residue
5. Cleavage & Deprotection: Peptide cleaved from resin; side-chain protecting groups removed
6. Purification: Preparative HPLC used to achieve high-purity final product

For longer peptides (>50 residues) or where SPPS is impractical, recombinant biological synthesis using E. coli or
yeast expression systems is employed. Native chemical ligation allows joining of SPPS fragments to produce larger
peptides.
Fig: Peptides are manufactured using solid phase FMOC or BOC chemistry methodologies on a PEG-
Polystyrene support resin

2.3 Recombinant Proteins

Recombinant proteins are produced by inserting the gene encoding the protein of interest into a suitable host
organism (expression system), which then acts as a biological factory to produce the protein at scale. This
approach underlies the production of insulin, erythropoietin, growth hormone, clotting factors, and many enzyme
replacement therapies.
Recombinant DNA Technology Workflow
• Gene identification and isolation from genomic or cDNA library
• Gene insertion into expression vector (plasmid) with strong promoter
• Transfection into host cell line (E. coli, CHO, HEK293, yeast)
• Selection of stable, high-expressing clones
• Scale-up through bioreactor cultivation
• Protein isolation, purification, formulation, and fill-finish

Host system selection is critical: E. coli (prokaryotic) is cost-effective and fast-growing but cannot perform post-
translational modifications (glycosylation). Mammalian cells (CHO, HEK293) produce glycosylated, properly folded
proteins resembling native human proteins, but are slower and more expensive to culture.

2.4 Monoclonal Antibodies (mAbs)

Monoclonal antibodies are immunoglobulins produced by identical immune cells (clones), each binding to a single,
specific antigen epitope. They represent the fastest-growing class of therapeutic biologics, with applications in
oncology, autoimmune diseases, and infectious diseases.

mAb Production: Hybridoma Technology

7. Immunization of a mouse or rabbit with the target antigen
8. Isolation of spleen B-lymphocytes producing antigen-specific antibodies
9. Cell fusion with immortal myeloma cells to create hybridomas
10. Screening and selection of hybridoma clones producing the desired antibody
11. Scale-up production; antibody isolation and purification

Modern mAbs have evolved from murine (fully mouse) to chimeric (human/mouse), humanized (~95% human),
and fully human antibodies — each with reduced immunogenicity. Examples: Adalimumab (Humira®) for
rheumatoid arthritis; Trastuzumab (Herceptin®) for HER2+ breast cancer; Pembrolizumab (Keytruda®) for multiple
cancers.

mAb Type % Human Examples Key Feature

Murine (-omab) 0% Muromonab First generation; high

immunogenicity

Chimeric (-ximab) ~65% Rituximab, Infliximab Reduced immunogenicity

Humanized (-zumab) ~95% Trastuzumab, Bevacizumab Minimal immune reactions

Fully Human (-umab) 100% Adalimumab, Ipilimumab Lowest immunogenicity

2.5 Vaccines
Vaccines are biological preparations that stimulate the immune system to recognize and mount a protective
response against specific pathogens. As APIs, vaccine antigens must be manufactured to strict identity, purity,
potency, and consistency standards.
• Live attenuated vaccines: Weakened pathogen (MMR, oral polio, yellow fever)
• Inactivated/killed vaccines: Pathogen killed by heat or chemical (influenza, hepatitis A)
• Subunit vaccines: Purified protein antigens (hepatitis B surface antigen, pertussis toxoid)
• Virus-like particles (VLPs): Self-assembling protein shells without genetic material (Gardasil® for HPV)
• mRNA vaccines: Lipid nanoparticle-encapsulated mRNA encoding antigen (COVID-19 Pfizer/Moderna)
• Viral vector vaccines: Non-replicating adenovirus delivering antigen gene (AstraZeneca COVID-19)

2.6 Gene & Cell Therapies

Gene and cell therapies represent the frontier of biological medicine — interventions that modify, replace, or
supplement genes or cells to treat disease at its root cause.

Gene Therapy
Gene therapy delivers functional genetic material into patient cells to correct defective or missing genes. Delivery
vehicles include viral vectors (adeno-associated virus/AAV, lentivirus, adenovirus) or non-viral methods (lipid
nanoparticles, electroporation). Examples: Luxturna® (RPE65 mutation causing blindness), Zolgensma® (SMA type
1).

Cell Therapy — CAR-T

Chimeric Antigen Receptor (CAR) T-cell therapy is a highly personalized immunotherapy that genetically engineers
a patient's own T cells to identify and kill cancer
cells. It is used primarily for relapsed or refractory
blood cancers, including certain leukemias,
lymphomas, and multiple myeloma. The process
involves collecting, modifying, and re-infusing
cells, which can lead to complete remission in
advanced cases. Chimeric Antigen Receptor T-cell
(CAR-T) therapy involves isolating a patient's T-
cells, genetically engineering them to express a
receptor targeting a tumor antigen, expanding
them ex vivo, and reinfusing them to attack cancer
cells. Examples: Kymriah® (tisagenlecleucel) for B-
cell ALL; Yescarta® (axicabtagene ciloleucel) for
DLBCL.
The Process: Involves apheresis (cell collection),
genetic engineering (using viral vectors to
introduce the CAR gene), laboratory expansion,
and re-infusion into the patient.
 Section III: Manufacturing Science

3.1 Raw Material Sourcing

The quality of an API is fundamentally dependent on the quality of its starting materials, reagents, solvents, and
catalysts. Raw material sourcing encompasses identification of supply chain partners, qualification of vendors, and
establishment of specifications aligned with ICH Q7 and pharmacopoeial standards.
• Key Starting Materials (KSMs): Defined in regulatory filings as starting points for synthesis
• Intermediates: Compounds formed during synthesis between KSMs and final API
• Reagents and catalysts: Reaction enablers — must be pharma-grade or meet defined specifications
• Solvents: Governed by ICH Q3C (Class 1 = avoid; Class 2 = limit; Class 3 = acceptable)
• Packaging materials: Direct contact materials must be compatible, tested for extractables/leachables

3.2 Supplier Qualification

Supplier qualification is a GMP requirement ensuring that vendors of critical materials are capable of consistently
meeting quality standards. The qualification process typically includes:
1. Supplier questionnaire and self-assessment
2. Review of quality management system documentation
3. On-site audit (or remote audit) by the pharmaceutical manufacturer
4. Analytical testing of multiple batches against predefined specifications
5. Formal approval and inclusion in the Approved Supplier List (ASL)
6. Periodic re-qualification and change notification agreements

📌 Regulatory Requirement
ICH Q7 Section 7 mandates that API manufacturers evaluate, audit, and approve suppliers of APIs,
intermediates, and critical materials. Supplier changes may require regulatory notification (CBE-30 or
prior approval supplement in the US).

3.3 Batch Manufacturing

Traditional API manufacturing is conducted in discrete batches — a defined quantity of material processed
through a series of unit operations using fixed equipment and procedures. Each batch is traceable, tested against
release specifications, and documented in batch manufacturing records (BMRs).

Typical Batch Manufacturing Flow

1. Weigh and dispense raw materials (controlled area, calibrated balances)
2. Chemical reaction(s) in reactor vessels (jacketed, with agitation, temperature control)
3. In-process controls (IPCs): pH, temperature, conversion by HPLC or TLC
4. Workup: Extraction, washing, phase separation
 5. Isolation: Filtration or centrifugation
6. Drying: Tray drier, fluidized bed, spray drier
7. Milling/micronization (if required for particle size specification)
8. Blending (homogenization of the batch)
9. In-process and final release testing
10. Packaging, labeling, storage in quarantine; QP release

3.4 Continuous / Flow Chemistry

Flow chemistry (continuous manufacturing) represents a paradigm shift from batch to uninterrupted processing.
In flow chemistry, reactants are pumped continuously through narrow-diameter reactor tubes or microreactors,
enabling precise control of temperature, pressure, mixing, and residence time.

Advantages of Flow Chemistry

• Enhanced heat and mass transfer — exotherms managed safely in small reaction volumes
• Rapid mixing — millisecond-scale mixing enables access to unstable intermediates
• Improved safety — small volumes reduce hazardous inventory
• Telescoping: Multiple reactions conducted sequentially without isolation
• Real-time PAT integration — in-line spectroscopic monitoring
• Consistent quality — reduced batch-to-batch variability
• Smaller plant footprint — modular, scalable reactors

FDA and EMA strongly encourage continuous manufacturing as part of the Quality by Design (QbD)
paradigm. ICH Q13 (Continuous Manufacturing for Drug Substances and Drug Products) provides the
regulatory framework adopted in 2022.

Feature Batch Manufacturing Flow / Continuous Manufacturing

Scale Fixed (defined batch size) Scalable by run time

Temperature control Jacket cooling — limited heat Excellent heat transfer in

transfer microreactors

Safety Large hazardous volumes Small volumes — inherently safer

Impurity control Post-reaction workup Continuous in-line monitoring

Equipment size Large reactor vessels Compact, modular reactors

Regulatory maturity Well-established Emerging — ICH Q13 guidance

Ideal for Multi-step complex synthesis Hazardous, fast, or photochemical

reactions
3.5 Scale-up Principles
Scale-up is the process of transferring a chemical process from laboratory or pilot scale to commercial
manufacturing scale while maintaining product quality and process performance. This is one of the most
technically challenging aspects of API development.

Key Scale-up Challenges

• Heat transfer: Surface-to-volume ratio decreases at scale; cooling/heating becomes less efficient
• Mass transfer / mixing: Agitator design, impeller tip speed, and Reynolds number must be considered
• Reaction homogeneity: Gradients in temperature and concentration form at large scale
• Filter cake washability and dryer efficiency: Change significantly at scale
• Solvent recovery and waste management: Must be designed into the process

Scale-up typically proceeds through defined stages: bench scale (grams), laboratory scale (100s of grams), pilot
scale (kg to tens of kg), and commercial scale (hundreds of kg to tons). Process analytical technology (PAT) and
Design of Experiments (DoE) are essential tools for understanding process at each scale.

3.6 Utilities: HVAC, WFI & Clean Steam

GMP API manufacturing requires critical utility systems that maintain environmental controls and provide high-
purity process materials.

HVAC (Heating, Ventilation & Air Conditioning)

HVAC systems control temperature, humidity, air pressure differentials, and particulate contamination in
manufacturing areas. Classified cleanrooms (ISO 5–8) are maintained for critical operations. Air pressure
differentials prevent cross-contamination between rooms handling different compounds (particularly important
for cytotoxics and hormones).

Water for Injection (WFI)

WFI is the highest purity grade of pharmaceutical water, used for preparation of injectable products and as a final
rinse for equipment. It is produced by distillation or reverse osmosis followed by ultrafiltration (Ph. Eur. allows
cold membrane process since 2017). WFI must meet pharmacopoeial limits for total organic carbon (TOC ≤ 0.5
mg/L), conductivity, bacterial endotoxins, and microbial limits.

Clean Steam
Clean steam (pharmaceutical-grade steam) is used for sterilization of equipment and product-contact surfaces.
Unlike utility steam (which contains boiler additives), clean steam is generated from purified water and meets
stringent quality requirements including non-pyrogenicity.
 Section IV: Upstream & Downstream Processing

4.1 Upstream Processing

Upstream processing encompasses all steps from cell banking and inoculum preparation through fermentation or
cell culture to harvest. It is where the biologic API is actually produced by living cells.
• Cell bank system: Master Cell Bank (MCB) and Working Cell Bank (WCB) — cryopreserved,
characterized, tested
• Seed train: Sequential scale-up in shake flasks, seed bioreactors before production bioreactor
inoculation
• Culture media: Chemically defined media (CDM) preferred for regulatory clarity; serum-free for safety
• Process parameters: Temperature, pH, dissolved oxygen (DO), agitation, CO₂, osmolality — all
monitored and controlled
• Feeding strategy: Batch, fed-batch (most common), or perfusion culture

4.2 Bioreactors
Bioreactors are closed, aseptic vessels designed to support controlled growth of microorganisms or mammalian
cells for production of biological APIs. They are the central unit operation in bioprocess manufacturing.
Bioreactors support biological processes using living organisms like microbes, cells, or enzymes to produce
proteins, metabolites, or biofuels. They maintain gentle, life-sustaining conditions such as 37°C, pH ~7.2, and
steady oxygen supply to prevent cell damage. Sterility is critical to avoid contamination, and mixing uses low-shear
impellers or airlift systems for even nutrient distribution without harming fragile cells.
Common types include stirred-tank (versatile for large-scale fermentation with precise control of pH and oxygen),
airlift (gentle circulation via air bubbles, ideal for shear-sensitive plant cells), bubble column (simple, high oxygen
transfer), fluidized bed, and packed bed reactors. Operations run in batch, fed-batch, or continuous modes, with
downstream processing for product purification like filtration or chromatography.
This benchtop bioreactor system shows multiple vessels connected to a control unit for monitoring microbial
growth.

Types of Bioreactors with example

Bioreactor Type Operating Principle Applications

Stirred Tank Reactor Mechanical agitation by mAbs, recombinant proteins (CHO, E. coli)
(STR) impellers; most widely used

Airlift Reactor Gas sparging drives circulation; Plant cells, sensitive mammalian cells
gentle mixing

Single-Use Bioreactor Disposable plastic bag; no Clinical batches; flexible multi-product facilities
cleaning/sterilization

Wave Bioreactor Rocking motion agitates bag; Small-scale cell culture, seed trains
excellent gas transfer
 Perfusion Bioreactor Continuous media feed + bleed; High-titer production, continuous
high cell density manufacturing

Chemical Reactors
Chemical reactors facilitate abiotic reactions using synthetic catalysts, heat, or pressure to produce commodities
like ammonia, plastics, or pharmaceuticals. They endure harsh conditions—up to 500°C and 150 atm—for fast
kinetics, prioritizing corrosion resistance and energy efficiency over biological viability.
Types range from glass/stainless steel batch reactors, high-pressure vessels, and glass-lined reactors to continuous
flow systems like tubular, fixed bed, fluidized bed, and microchannel reactors. Controls focus on temperature,
pressure, and flow rates, with high-shear mixing for rapid homogenization.

4.3 Downstream Processing (DSP)

Downstream processing refers to all purification steps that convert the crude cell culture harvest into a highly
purified, formulated, and stable biologic API. DSP typically contributes 50–80% of total manufacturing cost for
biologics.

Primary Recovery
• Centrifugation or microfiltration to remove cells and cell debris from harvest
• Depth filtration for clarification of harvest fluid

Capture Chromatography
• Protein A affinity chromatography (gold standard for mAbs): Highly selective; removes >99.9% of
impurities in one step
• Other capture steps: Ion exchange (IEX), hydrophobic interaction chromatography (HIC)
Polishing Chromatography
• Anion exchange (AEX): Removes HCP (host cell proteins), DNA, endotoxins, and viruses
• Cation exchange (CEX): Removes aggregates and product-related impurities
• Size exclusion chromatography (SEC): Separates aggregates from monomeric protein

Viral Clearance
• Low pH hold: Virus inactivation step (pH ~3.5–4.0 for 30–60 min)
• Nanofiltration (virus filtration): 20 nm filters provide robust viral removal

4.4 Fermentation Technology

Microbial fermentation is used to produce small molecule APIs (via biosynthesis, e.g., antibiotics), amino acids,
vitamins, and some recombinant proteins using bacterial or fungal hosts. It differs from mammalian cell culture
in faster growth rates, simpler media requirements, and higher cell densities.
• Batch fermentation: Fixed media; cells grow, produce, and are harvested at end
• Fed-batch fermentation: Nutrient feed added during run to extend production phase — most common
mode
• Continuous fermentation (chemostat): Constant feed and harvest; challenges with genetic stability
• Key monitored parameters: Dissolved oxygen, pH, temperature, agitation, foam, off-gas analysis (CO₂
evolution rate as indirect measure of growth)
Antibiotics (penicillin, streptomycin, erythromycin), statins (lovastatin), and immunosuppressants (cyclosporin,
tacrolimus) are manufactured via fermentation followed by downstream isolation and purification.
 Section V: Purification & Analytics

5.1 Filtration
Filtration is a mechanical separation process in which solids are separated from liquids using a porous medium
that retains particles while allowing the liquid (filtrate) to pass through. In API manufacturing, filtration is used at
multiple stages — for clarification, isolation of API solids, and sterile filtration of solutions.

Filtration Types
• Cake filtration: Solids build up on filter medium as cake; typical in API isolation (Nutsche filters, filter
dryers, centrifuges)
• Depth filtration: Solids trapped within porous matrix; used for bioprocess clarification
• Membrane filtration: Microporous membranes; microfiltration (0.1–10 µm), ultrafiltration (UF, 1–100
nm), nanofiltration
• Sterile filtration: 0.22 µm membrane removes all viable microorganisms; used before fill-finish of
injectables

Nutsche Filter / Filter Dryer

A Nutsche filter (or ANFD — Agitated Nutsche Filter Dryer) is a closed-vessel system where slurry is charged, solids
retained on filter media, and liquid drained under vacuum or pressure. After filtration, the cake can be washed,
reslurried, and dried in the same vessel under vacuum with jacket heating. Widely used in pharma API
manufacturing for GMP-compliant, contained, solvent recovery-compatible isolation.

5.2 Centrifugation
Centrifugation uses centrifugal force to separate particles by density. In API manufacturing, industrial centrifuges
isolate crystalline or amorphous solids from mother liquors, wash the solids, and partially dewater the cake before
drying.
• Basket centrifuges: Perforated bowl retains cake; liquid passes through; common in pharmaceutical API
plants
• Disc-stack centrifuges: Used for liquid-liquid separation or for very fine particles in bioprocessing
• Decanter centrifuges: Continuous separation of solids from slurries
In bioprocessing, disk-stack centrifuges are used during primary recovery to separate cells from culture harvest at
speeds of 5,000–15,000 × g. The choice between filtration and centrifugation depends on particle size, density,
cake compressibility, and processing volume.

5.3 Chromatography
Chromatography is the single most important purification technique in API manufacturing, particularly for
biologics. It separates molecules based on differential interaction with a stationary phase as they move through
in a mobile phase.
 Chromatography Mode Separation Basis Pharmaceutical Application

Affinity (Protein A) Specific ligand binding mAb capture — highly selective

Ion Exchange (IEX) Charge-based interactions Biologic polishing, DNA/HCP removal

Hydrophobic Interaction Hydrophobicity under high Biologic polishing, aggregate removal

(HIC) salt

Size Exclusion (SEC) Molecular size Aggregate removal; analytical characterization

Reversed Phase (RP-HPLC) Hydrophobicity Small molecule API purity testing (analytical)

Normal Phase (NP-HPLC) Polarity Chiral separation of enantiomers

Chiral HPLC Stereospecific interactions Enantiomeric purity testing

5.4 Crystallization
Crystallization is the unit operation of choice for final API isolation and purification in small molecule
manufacturing. A supersaturated solution is induced to form a crystalline solid, leaving most impurities in the
mother liquor. Crystal form (polymorph), size distribution, shape, and purity are all controlled through
crystallization process design.
• Cooling crystallization: Reduce temperature of hot saturated solution to induce crystallization
• Anti-solvent crystallization: Add miscible non-solvent to reduce API solubility
• Reactive crystallization: Chemical reaction produces insoluble product directly
• Evaporative crystallization: Solvent removal by evaporation

📌 Polymorphism
Many APIs can crystallize in multiple polymorphic forms with different physical properties (solubility,
stability, bioavailability). ICH Q6A requires polymorphic characterization. Ritonavir's market
withdrawal in 1998 due to Form II polymorph emergence is a classic case study in pharmaceutical
science.

5.5 Drying
Drying removes residual solvents from isolated API solids to meet pharmacopoeial and specification limits (ICH
Q3C). The choice of drying method depends on the API's thermal stability, solvent system, particle size, and
required throughput.

Drying Method Mechanism Best For

Tray Drier Static bed; convective air drying Non-thermolabile, robust materials

Fluid Bed Drier (FBD) Fluidized particles; rapid drying Granules; thermally stable APIs

Vacuum Tray Drier Reduced pressure; low Thermolabile APIs; solvent-wet cakes
temperature

Spray Drier Atomized droplet drying Amorphous dispersions; nanoparticles

 Freeze Drier Sublimation under vacuum Biologics; heat-sensitive APIs
(Lyophilizer)

ANFD (Agitated In-situ vacuum drying in filter Contained; hazardous; potent APIs
Nutsche Filter Dryer) vessel

5.6 PAT (Process Analytical Technology) Tools

PAT is an FDA/ICH framework for designing, analyzing, and controlling pharmaceutical manufacturing processes
through timely measurements of critical quality attributes (CQAs) and critical process parameters (CPPs) during
processing, thereby ensuring final product quality.
• Near-Infrared Spectroscopy (NIR): In-line monitoring of moisture, blend uniformity, polymorphic form
• Raman Spectroscopy: Identifies crystal form, monitors crystallization and reaction completion
• In-line HPLC/UV: Real-time conversion monitoring in flow chemistry or reaction vessels
• Particle Size Analysis (FBRM, PVM): In-situ crystal size monitoring during crystallization
• pH, DO, and OUR probes: Standard bioprocess monitoring
• Mass Spectrometry: Real-time off-gas analysis in fermentation
• Multivariate Data Analysis (MVDA): Chemometric models correlating process data to quality attributes

PAT is a cornerstone of Quality by Design (QbD) and continuous manufacturing strategies, enabling
real-time release testing (RTRT) which eliminates the need for extensive end-product testing when
process understanding is sufficiently deep (ICH Q8, Q9, Q10).
 Section VI: Quality & Regulations

6.1 Good Manufacturing Practices (GMP)

GMP is a system of regulations that ensures pharmaceutical products are consistently produced and controlled
according to quality standards appropriate for their intended use. GMP covers all aspects of production — from
raw materials, premises, and equipment to the training of staff and their personal hygiene.
• GMP is not prescriptive — it defines what must be achieved, not exactly how
• Key GMP elements: Personnel (training, hygiene), Premises & Equipment (design, qualification,
maintenance), Documentation, Production, QC testing, Complaints & Recalls, Self-inspections
• GMP failure consequences: Regulatory warning letters, import alerts, consent decrees, market
withdrawals

6.2 ICH Q7 — GMP for Active Pharmaceutical Ingredients

ICH Q7 is the primary international guideline governing the manufacture of APIs. It defines GMP requirements
specifically for API manufacturers, covering the entire manufacturing process from defined starting materials
through final API packaging.

ICH Q7 Key Sections

ICH Q7 Section Topic

Section 1–3 Introduction, quality management, personnel

Section 4 Buildings and facilities

Section 5 Process equipment

Section 6 Documentation and records

Section 7 Materials management

Section 8 Production and in-process controls

Section 9 Packaging and labeling

Section 10 Storage and distribution

Section 11 Laboratory controls

Section 12 Validation

Section 13 Change control

Section 14 Rejection and reuse of materials

Section 15 Complaints and recalls

Section 16 Contract manufacturers

Section 17 Agents, brokers, distributors

Section 18 Specific guidance for API by cell culture / fermentation

 Section 19 APIs for use in clinical trials

Section 20 Glossary

6.3 ISO Systems

International Organization for Standardization (ISO) standards provide frameworks for quality management
applicable to pharmaceutical API manufacturers alongside GMP requirements.
• ISO 9001: Quality Management System — the foundational QMS standard; process approach, risk
thinking, continual improvement
• ISO 14001: Environmental Management System — waste, emissions, sustainability
• ISO 13485: Medical devices QMS — sometimes relevant for drug-device combination products
• ISO 17025: Laboratory competence — relevant for QC testing laboratories
• ISO 45001: Occupational health and safety — relevant for chemical manufacturing environments

6.4 Validation
Validation is the documented evidence that a process, system, or method consistently produces a result meeting
its predetermined acceptance criteria. Validation is a GMP requirement and a fundamental quality assurance
activity in API manufacturing.

Types of Validation
• Process validation (PV): Demonstrates that a manufacturing process consistently produces an API
meeting its specifications (prospective, concurrent, retrospective, continuous process verification)
• Cleaning validation: Demonstrates that cleaning procedures effectively remove API residues,
degradants, and cleaning agents below acceptable limits (often MACO-based calculations)
• Analytical method validation: Demonstrates that an analytical procedure is suitable for its intended
purpose — ICH Q2(R1) parameters: specificity, linearity, accuracy, precision, range, LOD, LOQ,
robustness
• Computer system validation (CSV): Ensures software and computerized systems perform as intended —
GAMP 5 framework
• Equipment/utilities qualification: IQ (Installation Qualification), OQ (Operational Qualification), PQ
(Performance Qualification)

6.5 Documentation
GMP documentation creates a comprehensive, traceable record of all manufacturing activities, decisions, and
quality events. 'If it isn't documented, it didn't happen' is a cardinal principle of pharmaceutical GMP.
• SOPs (Standard Operating Procedures): Step-by-step instructions for all significant operations
• Batch Manufacturing Records (BMRs): Complete record of each production batch from start to finish
• Analytical Method Procedures: Instructions for QC testing
• Specifications: Defined limits for raw materials, intermediates, and APIs
 • Change control forms: Documented evaluation and approval of any change to process, materials, or
equipment
• Deviation and CAPA reports: Investigation and corrective/preventive actions for out-of-specification
results or process failures
• Technology transfer documentation: Process, method, and knowledge transfer between sites

6.6 Regulatory Pathways: FDA / EMA / CDSCO

APIs are reviewed by regulatory authorities as part of drug product marketing authorization applications. The key
regulatory submissions and bodies are:

FDA (United States Food & Drug Administration)

• Drug Master File (DMF) Type II: Filed by API manufacturer; references by finished product applicant
(NDA/ANDA)
• NDA (New Drug Application) — 505(b)(1): Original NDA with full clinical data; for innovator APIs
• 505(b)(2) NDA: Hybrid; relies partly on existing FDA findings; for new formulations or new routes
• ANDA (Abbreviated NDA): Generic API + finished product; demonstrates bioequivalence; no clinical trials
needed

EMA (European Medicines Agency)

• CEP (Certificate of Suitability, Ph. Eur.): European API quality certification issued by EDQM
• ASMF (Active Substance Master File): European equivalent of US DMF
• MAA (Marketing Authorization Application): Full dossier in CTD format

CDSCO (India — Central Drugs Standard Control Organization)

• Governed by Drugs & Cosmetics Act (1940) and Rules (1945)
• API manufacturing license required under Schedule M (GMP compliance)
• WHO-GMP certification: Required for export; issued by CDSCO after inspection
• SUGAM portal: Online submission system for drug approvals in India
 Section VII: Advanced Topics

7.1 Biosimilars
A biosimilar is a biologic medicine that is highly similar to an already-approved reference biologic (originator) with
no clinically meaningful differences in terms of safety, purity, and potency. Biosimilars are not identical to their
reference products (unlike generic small molecules) due to the inherent variability of biologic manufacturing
processes.

Biosimilar Development Pathway

12. Analytical similarity study: Extensive physicochemical and functional characterization comparing
biosimilar to reference across multiple batches
13. Non-clinical studies: PK/PD studies, toxicology if needed
14. Clinical PK bridging study: Demonstrating PK equivalence (usually in healthy volunteers)
15. Clinical efficacy and safety study: In sensitive patient population to confirm no clinically meaningful
differences
16. Regulatory submission: FDA 351(k) or EMA biosimilar guideline pathway

Biosimilars are driving down biologic drug costs globally. Adalimumab (Humira®) biosimilars launched in Europe
after patent expiry reduced costs by 80%+. The US FDA has approved dozens of biosimilars under the BPCI Act
(2010).

7.2 Antibody-Drug Conjugates (ADCs)

ADCs are a class of targeted cancer therapy combining the specificity of a monoclonal antibody with the cytotoxic
potency of a small molecule drug (payload), linked via a chemical linker. They are often described as 'guided
missiles' — the antibody navigates to cancer cells expressing the target antigen, where the payload is released to
kill the cell.

ADC Components
• Antibody: Typically IgG1; targets a tumor-associated antigen (TAA) expressed on cancer cells
• Linker: Connects antibody to payload; cleavable (pH, protease, disulfide) or non-cleavable
• Payload (cytotoxin): Highly potent (pM range); auristatins (MMAE, MMAF), maytansinoids (DM1, DM4),
calicheamicins, camptothecin analogs (DXd)
• Drug-to-Antibody Ratio (DAR): Typically 2–8; critical quality attribute affecting PK, efficacy, and safety

Examples: Kadcyla® (ado-trastuzumab emtansine, T-DM1) for HER2+ breast cancer; Enhertu® (trastuzumab
deruxtecan, T-DXd) — now a blockbuster; Adcetris® (brentuximab vedotin) for Hodgkin lymphoma.
7.3 Personalized Medicine
Personalized (precision) medicine tailors medical treatment to individual patient characteristics — genomic
profile, biomarker status, disease subtype, or other individual factors. APIs in precision medicine may be mass-
produced (targeted therapy for defined patient subgroup) or individually manufactured (bespoke therapies).
• Companion diagnostics: Co-developed diagnostic test and targeted API (e.g., EGFR mutation test +
erlotinib for NSCLC)
• Pharmacogenomics: Genetic variation affecting drug metabolism (CYP2D6 polymorphisms affecting
codeine, antidepressants)
• CAR-T therapies: Patient-specific T-cell therapies manufactured individually
• Neoantigen vaccines: Cancer vaccines targeting unique mutations in each patient's tumor
• Oligonucleotide therapies: ASO (antisense oligonucleotides), siRNA designed for specific genetic targets

7.4 Artificial Intelligence in API Manufacturing

AI and machine learning (ML) are transforming API development and manufacturing across the value chain —
from molecular design to process control and quality prediction.

Key Applications of AI in API Manufacturing

• De novo drug design: AI models (generative AI, reinforcement learning) propose novel molecular
structures with desired properties
• Synthesis route prediction: AI predicts optimal synthetic routes (e.g., Chematica/Synthia by Merck)
• Reaction outcome prediction: ML models predict yield, selectivity, and product distribution
• Process optimization: AI-driven Design of Experiments (DoE) identifies optimal process parameters
faster
• Real-time process control: AI integrates PAT data streams to adjust process parameters autonomously
• Predictive quality analytics: Models predict batch outcomes from in-process data, enabling early failure
detection
• Supply chain optimization: AI models predict demand, identify supply chain risks, and optimize inventory
• Regulatory intelligence: NLP models analyze regulatory documents and predict submission outcomes
 Section VIII: Industrial Case Studies

8.1 DEG (Diethylene Glycol) Contamination

One of the most tragic case studies in pharmaceutical quality is the mass poisoning events caused by diethylene
glycol (DEG) substituting for glycerin or propylene glycol in liquid pharmaceutical formulations.

Key Incidents
• 1937 — USA (Sulfanilamide Elixir): 107 deaths; solvent used was DEG; direct trigger for the 1938 Federal
Food, Drug, and Cosmetic Act requiring pre-market safety demonstration
• 1986 — Spain (cough syrup): Multiple deaths from DEG-contaminated product
• 1996 — Haiti (acetaminophen syrup): 89 deaths, primarily children; DEG imported fraudulently as
glycerin
• 2007 — Panama (Alcodet/cold medicine): 100+ deaths from DEG-contaminated glycerin sourced
through multiple broker chains from China
• 2022–23 — India/Gambia/Uzbekistan/Indonesia: Children's syrups manufactured in India contained
DEG/EG above limits; 300+ child deaths globally; major regulatory fallout

📌 Regulatory Lessons
These incidents highlight critical lessons: (1) Supplier qualification cannot be bypassed; (2) Identity
testing (IR, GC) must be performed on every lot of critical excipients regardless of COA; (3) Supply
chain transparency and broker oversight are essential; (4) WHO and pharmacopoeias mandate
specific tests for glycerin (limits of DEG to <0.10%).

8.2 Heparin Contamination (2008)

In 2007–2008, a global crisis emerged when contaminated heparin sodium (an anticoagulant API) caused at least
81 deaths in the United States and hundreds of adverse reactions worldwide. The contamination was traced to
crude heparin sourced from China.

The Contaminant: Oversulfated Chondroitin Sulfate (OSCS)

OSCS was found in contaminated heparin lots at concentrations of up to 50%. OSCS was deliberately added
('economically motivated adulteration') as a cost-cutting measure — it mimics heparin in standard testing but
lacks anticoagulant activity and instead activates complement and contact pathways, causing anaphylactic
reactions.
• OSCS was not detected by the standard USP test (clotting assay) as it produced a similar result to
authentic heparin
• Detection required NMR spectroscopy and capillary electrophoresis (CE) — not part of standard
pharmacopoeial testing at the time
• Outcome: FDA issued import alerts; heparin manufacturing was brought under GMP scrutiny; USP and
Ph. Eur. updated monographs to include NMR and CE identity tests; crude heparin facilities in China
were inspected
 📌 Regulatory Impact
The heparin crisis led to FDA requiring inspection of foreign drug manufacturing plants, increased
scrutiny of raw material sourcing, and strengthening of the supply chain provisions in 21 CFR. It was
a pivotal moment in the globalization debate of pharmaceutical manufacturing.

8.3 Supply Chain Disruptions

The COVID-19 pandemic exposed severe vulnerabilities in the global pharmaceutical supply chain, particularly for
APIs. The concentration of API manufacturing in India and China — itself driven by decades of cost pressure —
created systemic risk that materialized dramatically in 2020–2021.

COVID-19 Impact on API Supply Chain

• Lockdowns in China (January–February 2020) disrupted production and export of KSMs and
intermediates
• India's export ban on 26 API categories (March 2020) caused global shortages of essential medicines
• Azithromycin, hydroxychloroquine, paracetamol — demand surged while supply disrupted
• API prices spiked 20–200% for many essential molecules

Systemic Vulnerabilities Exposed

• ~80% of US drug supply relies on APIs or their precursors from India or China
• Single-source API supply with no qualified backup suppliers
• Just-in-time inventory models with minimal safety stock
• Multi-tier supply chains with limited visibility beyond Tier 1 suppliers

Policy Responses
• India: PLI (Production Linked Incentive) scheme for domestic API manufacturing — ₹6,940 crore
approved
• USA: BARDA investments in domestic API manufacturing; Executive Order on essential medicines supply
chain
• EU: IPCEI (Important Projects of Common European Interest) for pharmaceutical supply chain
• Reshoring/nearshoring trends — manufacturers diversifying supply to multiple geographies

8.4 India as the Global API Hub

India has earned the title 'pharmacy of the world' — a testament to its dominant position in the global API
manufacturing landscape. This status was built over four decades through a combination of policy, talent,
infrastructure, and cost competitiveness.

India's API Industry Strengths

• Produces ~20–25% of global API volume by quantity; supplies APIs for ~50% of US generic drugs
 • Home to the world's largest number of FDA-approved drug manufacturing facilities outside the US
(~600+ plants)
• Cost advantage: API manufacturing costs 30–40% lower than Western manufacturers
• Talent pool: World's largest number of chemistry and pharmaceutical science graduates annually
• Generic drug dominance: Strong domestic generics industry drives API demand
• Hyderabad, Mumbai, Ahmedabad, Visakhapatnam — major API manufacturing hubs

Major Indian API Manufacturers

Company Key API Segments

Sun Pharma API Specialty, oncology, anti-infectives

Dr. Reddy's Laboratories APIs + generics; US & EU markets

Aurobindo Pharma β-lactam antibiotics, CVS APIs, ARVs

Divi's Laboratories Custom synthesis, nutraceuticals, generics APIs

Laurus Labs ARVs, oncology, custom synthesis

Cipla Respiratory, anti-HIV, anti-cancer APIs

Granules India Paracetamol, ibuprofen, metformin APIs

Challenges for India

• Dependence on China for KSMs and intermediates (~70% for some classes)
• Environmental compliance: Pollution from API clusters (Hyderabad HMDA belt) under regulatory
pressure
• Regulatory compliance: Repeated FDA warning letters to Indian plants; need for quality culture
improvement
• Price pressure: Thin margins in generic API business; need to move up value chain to complex/niche APIs
• R&D investment: Low compared to global innovators; transition to innovative APIs is the strategic
imperative

Strategic Outlook: India's PLI scheme for bulk drugs, combined with investments in biotech API
manufacturing, positions India to retain and grow its global API leadership while addressing the KSM
import dependency — a critical geopolitical and strategic priority for the country's pharmaceutical
sector.

— End of Study Notes —